Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
HealthDay on MSN16h
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate CancerFor patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
he asked. "What would you do for your unselected metastatic CRPC patients -- talazoparib with enzalutamide? [Radioligand therapy] with enzalutamide? Or are we still using ARPIs alone?" ...
Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) ...
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
GlobalData on MSN6d
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoCResults from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback